En Carta Diagnostics: A Game-Changer in Lyme Disease Detection
May 24, 2024, 9:35 am
En Carta Diagnostics, a pioneering startup based in Paris, France, has recently secured a substantial €1.5 million in Pre-Seed funding to advance its cutting-edge molecular diagnostic technology. Specializing in rapid Point-of-Care (POC) diagnostic kits, En Carta is on a mission to revolutionize the field of Lyme disease detection.
The company's innovative platform utilizes aptamers, molecules capable of binding with high specificity to target molecules, in a frugal cassette format. This unique approach allows for the rapid and accurate detection of various genetic, pathogenic, and veterinary indications, opening up a wide range of potential applications.
En Carta's decision to focus on Lyme disease as its initial application is strategic, given the alarming rise in cases of this debilitating vector-borne illness in the Northern Hemisphere. With a staggering 1.2 million cases reported annually, the need for early and precise diagnosis has never been more critical.
Traditional Lyme disease tests rely on detecting antibodies produced by the body in response to infection. However, these antibodies can take weeks to develop, leading to potential false-negative results in recently infected patients. En Carta's molecular diagnostic platform overcomes this limitation, offering a more accurate and rapid alternative for diagnosing Lyme disease.
Led by CEO Guillaume Horreard, En Carta has made significant strides since its inception in 2022. The company has developed five prototypes, published ten scientific papers showcasing the efficacy of its technology in detecting various pathogens, and secured a commercial contract with a prominent digital healthcare leader.
The recent funding round, spearheaded by CentraleSupélec Venture with participation from undisclosed angels, will enable En Carta to further develop its diagnostic kit for Lyme disease. The company aims to present preclinical data in early 2025, marking a significant milestone in its journey towards commercialization.
With the support of investors and industry experts, En Carta is poised to make a lasting impact in the field of Point-of-Care diagnostics. By providing healthcare practitioners with a reliable and efficient tool for early Lyme disease detection, the company is paving the way for improved patient outcomes and a more effective approach to managing this widespread health concern.
In a world where rapid and accurate diagnosis is paramount, En Carta Diagnostics stands out as a beacon of hope in the fight against Lyme disease. Through its innovative technology and unwavering commitment to advancing healthcare, the company is set to redefine the landscape of diagnostic testing and bring about positive change for patients worldwide.
The company's innovative platform utilizes aptamers, molecules capable of binding with high specificity to target molecules, in a frugal cassette format. This unique approach allows for the rapid and accurate detection of various genetic, pathogenic, and veterinary indications, opening up a wide range of potential applications.
En Carta's decision to focus on Lyme disease as its initial application is strategic, given the alarming rise in cases of this debilitating vector-borne illness in the Northern Hemisphere. With a staggering 1.2 million cases reported annually, the need for early and precise diagnosis has never been more critical.
Traditional Lyme disease tests rely on detecting antibodies produced by the body in response to infection. However, these antibodies can take weeks to develop, leading to potential false-negative results in recently infected patients. En Carta's molecular diagnostic platform overcomes this limitation, offering a more accurate and rapid alternative for diagnosing Lyme disease.
Led by CEO Guillaume Horreard, En Carta has made significant strides since its inception in 2022. The company has developed five prototypes, published ten scientific papers showcasing the efficacy of its technology in detecting various pathogens, and secured a commercial contract with a prominent digital healthcare leader.
The recent funding round, spearheaded by CentraleSupélec Venture with participation from undisclosed angels, will enable En Carta to further develop its diagnostic kit for Lyme disease. The company aims to present preclinical data in early 2025, marking a significant milestone in its journey towards commercialization.
With the support of investors and industry experts, En Carta is poised to make a lasting impact in the field of Point-of-Care diagnostics. By providing healthcare practitioners with a reliable and efficient tool for early Lyme disease detection, the company is paving the way for improved patient outcomes and a more effective approach to managing this widespread health concern.
In a world where rapid and accurate diagnosis is paramount, En Carta Diagnostics stands out as a beacon of hope in the fight against Lyme disease. Through its innovative technology and unwavering commitment to advancing healthcare, the company is set to redefine the landscape of diagnostic testing and bring about positive change for patients worldwide.